Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CABA Cabaletta Bio	$1.73 -7.5%	$1.60	$0.99 ▼ $9.25	$87.79M	2.81	1.63 million shs	3.33 million shs
COEP Coeptis Therapeutics	$7.72 -6.0%	$9.31	$2.31 ▼ $13.70	$27.13M	-0.59	117,576 shs	33,691 shs
PLX Protalix BioTherapeutics	$1.40 +2.2%	$2.08	$0.82 ▼ $3.10	$111.45M	-0.21	556,770 shs	402,711 shs
THTX Theratechnologies	$2.50 +1.6%	$2.62	$1.12 ▼ $3.13	$114.95M	0.6	813,133 shs	112,605 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CABA Cabaletta Bio	0.00%	-3.89%	-7.98%	-0.57%	-79.28%
COEP Coeptis Therapeutics	0.00%	-8.10%	-20.08%	-18.74%	+18.92%
PLX Protalix BioTherapeutics	0.00%	-9.09%	-18.60%	-43.78%	+22.81%
THTX Theratechnologies	0.00%	-1.19%	-4.21%	+58.23%	+89.39%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CABA Cabaletta Bio	2.6164 of 5 stars	4.5	1.0	0.0	0.0	2.0	0.8	0.6
COEP Coeptis Therapeutics	0.6251 of 5 stars	0.0	5.0	0.0	0.0	0.6	1.7	0.0
PLX Protalix BioTherapeutics	2.8302 of 5 stars	3.5	4.0	0.0	0.0	1.1	0.0	1.9
THTX Theratechnologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CABA Cabaletta Bio	3.00	Buy	$18.88	991.04% Upside
COEP Coeptis Therapeutics	0.00	N/A	N/A	N/A
PLX Protalix BioTherapeutics	3.00	Buy	$15.00	971.43% Upside
THTX Theratechnologies	4.00	Strong Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest COEP, PLX, CABA, and THTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	CABA Cabaletta Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
5/16/2025	CABA Cabaletta Bio	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$17.00 ➝ $13.00
5/15/2025	CABA Cabaletta Bio	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$23.00 ➝ $25.00
4/11/2025	THTX Theratechnologies	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
4/1/2025	CABA Cabaletta Bio	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$6.00 ➝ $3.00
4/1/2025	CABA Cabaletta Bio	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$10.00 ➝ $7.00
4/1/2025	CABA Cabaletta Bio	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00
4/1/2025	CABA Cabaletta Bio	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$30.00 ➝ $22.00
4/1/2025	CABA Cabaletta Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00

(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	$3.12 per share	N/A
COEP Coeptis Therapeutics	$62.87K	431.47	N/A	N/A	$1.61 per share	4.80
PLX Protalix BioTherapeutics	$59.76M	1.86	$0.08 per share	17.80	$0.47 per share	2.98
THTX Theratechnologies	$85.87M	1.34	N/A	N/A	($0.55) per share	-4.55

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CABA Cabaletta Bio	-$115.86M	-$2.54	N/A	N/A	N/A	N/A	-78.29%	-65.68%	8/6/2025 (Estimated)
COEP Coeptis Therapeutics	-$10.88M	-$5.80	N/A	∞	N/A	N/A	-282.39%	-127.23%	N/A
PLX Protalix BioTherapeutics	$8.31M	$0.04	N/A	4.52	N/A	-21.03%	-30.89%	-11.74%	N/A
THTX Theratechnologies	-$8.31M	-$0.08	N/A	35.71	N/A	-4.18%	N/A	-0.37%	7/9/2025 (Estimated)

Latest COEP, PLX, CABA, and THTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/21/2025	Q1 2025	CABA Cabaletta Bio	-$0.67	-$0.71	-$0.04	-$0.71	N/A	N/A
5/14/2025	Q1 2025	COEP Coeptis Therapeutics	N/A	-$1.11	N/A	-$1.11	N/A	N/A
5/9/2025	Q1	PLX Protalix BioTherapeutics	N/A	-$0.05	N/A	N/A	N/A	N/A
3/31/2025	Q4 2024	CABA Cabaletta Bio	-$0.65	-$0.65	N/A	-$0.65	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	N/A
COEP Coeptis Therapeutics	N/A	N/A	N/A	N/A	N/A
PLX Protalix BioTherapeutics	N/A	N/A	N/A	N/A	N/A
THTX Theratechnologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CABA Cabaletta Bio	N/A	3.96	3.96
COEP Coeptis Therapeutics	0.02	0.82	0.82
PLX Protalix BioTherapeutics	N/A	1.98	1.27
THTX Theratechnologies	N/A	1.08	0.88

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CABA Cabaletta Bio	N/A
COEP Coeptis Therapeutics	13.88%
PLX Protalix BioTherapeutics	16.53%
THTX Theratechnologies	N/A

Insider Ownership

Company	Insider Ownership
CABA Cabaletta Bio	11.25%
COEP Coeptis Therapeutics	24.25%
PLX Protalix BioTherapeutics	6.50%
THTX Theratechnologies	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CABA Cabaletta Bio	50	50.74 million	45.03 million	Optionable
COEP Coeptis Therapeutics	2	3.51 million	2.66 million	Not Optionable
PLX Protalix BioTherapeutics	200	79.61 million	69.00 million	Optionable
THTX Theratechnologies	140	45.98 million	N/A	Optionable

COEP, PLX, CABA, and THTX Headlines

Recent News About These Companies

Theratechnologies Inc. (NASDAQ:THTX) Short Interest Update

June 2, 2025 | marketbeat.com

Theratechnologies Reports on its Annual Meeting of Shareholders

May 29, 2025 | globenewswire.com

Theratechnologies announces annual shareholder meeting

May 4, 2025 | uk.investing.com

Theratechnologies Presents Novel Data at ACTHIV 2025 Underscoring Importance of Managing Excess Visceral Abdominal Fat (EVAF) in People with HIV

May 2, 2025 | globenewswire.com

Theratechnologies: A High-Risk, High-Reward Speculation As Shares Trade At 39% Discount To Future Pak's $3.51-$4.50 Offer

April 18, 2025 | seekingalpha.com

Is Theratechnologies Inc. (THTX) the Best Rising Penny Stock to Buy According to Analysts?

April 18, 2025 | msn.com

Theratechnologies to further evaluate potential sale of the company

April 16, 2025 | markets.businessinsider.com

Theratechnologies Provides Update on Sale Process

April 15, 2025 | financialpost.com

Theratechnologies Provides Update on Sale Process

April 15, 2025 | globenewswire.com

Theratechnologies Engages in Exclusive Acquisition Talks

April 15, 2025 | tipranks.com

Soleus Capital Issues Letter to The Board of Theratechnologies

April 12, 2025 | financialpost.com

Soleus Capital Issues Letter to The Board of Theratechnologies

April 12, 2025 | businesswire.com

Theratechnologies Responds to Future Pak's Press Release and Announces Exclusive Discussions with Another Potential Acquiror for the Sale of the Company

April 11, 2025 | globenewswire.com

Future Pak submits proposals to acquire Theratechnologies

April 11, 2025 | msn.com

Future Pak Submits Proposals to Acquire Theratechnologies Inc. ...

April 11, 2025 | gurufocus.com

Future Pak Submits Proposals to Acquire Theratechnologies Inc., Offering up to $255 Million in Total Value

April 11, 2025 | businesswire.com

Theratechnologies Stock Plummets On Disappointing Q1 Earnings, Full Year Forecast: Retail Sentiment Sours

April 9, 2025 | msn.com

Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements

April 9, 2025 | globenewswire.com

Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements

April 9, 2025 | globenewswire.com

Theratechnologies receives FDA approval of PAS for EGRIFTA SV sBLA

April 8, 2025 | markets.businessinsider.com

3THTX : Examining the Future: Theratechnologies's Earnings Outlook

April 8, 2025 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

COEP, PLX, CABA, and THTX Company Descriptions

Cabaletta Bio NASDAQ:CABA

$1.73 -0.14 (-7.49%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$1.75 +0.02 (+1.16%)

As of 08:35 AM Eastern

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Coeptis Therapeutics NASDAQ:COEP

$7.72 -0.49 (-5.97%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$7.87 +0.15 (+1.94%)

As of 07:00 AM Eastern

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.

Protalix BioTherapeutics NYSE:PLX

$1.40 +0.03 (+2.19%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$1.40 0.00 (0.00%)

As of 08:23 AM Eastern

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

Theratechnologies NASDAQ:THTX

$2.50 +0.04 (+1.63%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$2.57 +0.07 (+2.96%)

As of 08:22 AM Eastern

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time